Perspective Therapeutics, Inc.
CATX
$3.47
-$0.215-5.84%
AMEX
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -15.20% | 46.15% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -15.20% | 46.15% | |||
| Cost of Revenue | 16.58% | -65.93% | |||
| Gross Profit | -17.41% | 66.39% | |||
| SG&A Expenses | -1.70% | -4.90% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.72% | 4.95% | |||
| Operating Income | -10.11% | -4.48% | |||
| Income Before Tax | -21.03% | 56.93% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -21.03% | 54.68% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -18.20% | 54.75% | |||
| EBIT | -10.11% | -4.48% | |||
| EBITDA | -10.45% | 47.75% | |||
| EPS Basic | -15.21% | 55.71% | |||
| Normalized Basic EPS | -17.96% | 2.12% | |||
| EPS Diluted | -15.21% | 77.93% | |||
| Normalized Diluted EPS | -17.96% | 2.12% | |||
| Average Basic Shares Outstanding | 2.60% | 2.17% | |||
| Average Diluted Shares Outstanding | 2.60% | 2.17% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||